



06-07-04

RCE/1651#  
IFW

Atty. Docket No. TAK03 P-323 (F-7178)

PATENT

CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that this paper, together with all enclosures identified herein, are being deposited with the United States Postal Service as Express Mail, using label No. EV 411645612 US, addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

June 4, 2004

Date

*Deborah A. Witvoet*  
Deborah A. Witvoet

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1651  
Examiner : Francisco C. Prats  
Applicants : Yoshihito Ikeda et al.  
Appln. No. : 10/018,770  
Filing Date : December 17, 2001  
Confirmation No. : 2012  
For : DRUG COMPOSITION CONTAINING A LECITHIN-MODIFIED SUPEROXIDE DISMUTASE

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

**REQUEST FOR CONTINUED EXAMINATION (RCE)**  
**(37 C.F.R. §1.114)**

1. Applicants hereby request continued examination, in accordance with 37 C.F.R. §1.114, for the above-identified application.
2. This request is being submitted prior to abandonment of the application, and prior to payment of issue fee.
3. Enclosed herewith are:

An Amendment (including attachments A-C), and  
Combination Claims As Amended Cover Sheet and Petition For Extension of  
Time (in duplicate).

(Request for Continued Examination (RCE) (37 C.F.R. §1.114) [9-64]—page 1 of 2)

Applicants : Yoshihito Ikeda et al.  
Appln. No. : 10/018,770  
Page : 2

**TOTAL FEE(S) DUE**

4. The total fee due is:

Continued Prosecution Fee (§ 1.17(e))	<u>\$385.00</u>
Fee(s) for additional claims (if any) (§ 1.16(b)-(d))	\$ <u>0.00</u>
Extension of time fee (if any) (§ 1.17(a)(1)-(4))	<u>\$420.00</u>
Total Fee Due	<u>\$805.00</u>

**PAYMENT OF FEE(S) DUE**

5. A check is attached in the amount of \$805.00 for the filing fee for this Request For Continued Examination (RCE).
6. Please charge any required additional fee(s) for §1.17(e), §1.16(b)-(d) and/or §1.17(a)(10)-(4) to Deposit Account No. 16-2463.

Customer No.: 000,277.


Respectfully submitted,

YOSHIHITO IKEDA ET AL.

By: Price, Heneveld, Cooper,  
DeWitt & Litton, LLP

June 4, 2004  
Date

GJE/daw  
TAK03 P-323

  
\_\_\_\_\_  
Gunther J. Evanina  
Registration No. 35 502  
695 Kenmoor, S.E.  
Post Office Box 2567  
Grand Rapids, Michigan 49501  
(616) 949-9610

Atty. Docket No. TAK03 P-323 (F-7178)  
Express Mail No. EV 411645612 US

Applicants : Yoshihito Ikeda et al.  
Appln. No. : 10/018,770  
Page : 2

X Small entity status of this application under 37 C.F.R. §§ 1.9 and 1.27 has been established by a verified statement previously submitted or is enclosed.

     No additional fee is required.

     A fee of                  to cover the cost of the additional claims added by this response is enclosed.


X A fee of \$420 to cover Petition for Extension of Time is enclosed.

X A check in the amount of \$420 is enclosed to cover the above fee.

X Please charge any additional fees or credit overpayment to Deposit Account 16 2463.  
A duplicate copy of this sheet is attached.

PRICE, HENEVELD, COOPER,  
DEWITT & LITTON, LLP

June 4, 2004  
Date

  
Gunther J. Evanina  
Registration No. 35 5022  
695 Kenmoor, S.E.  
Post Office Box 2567  
Grand Rapids, Michigan 49501  
(616) 949-9610

GJE/daw



Atty. Docket No. TAK03 P-323 (F-7178)  
Express Mail No. EV 411645612 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1651  
Examiner : Francisco C. Prats  
Applicants : Yoshihito Ikeda et al.  
Appln. No. : 10/018,770  
Filing Date : December 17, 2001  
Confirmation No. : 2012  
For : DRUG COMPOSITION CONTAINING A LECITHIN-MODIFIED SUPEROXIDE DISMUTASE

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

**AMENDMENT**

In response to the Advisory Action mailed April 2, 2004, and further to the Request For Continued Examination filed herewith, Applicants request further consideration and examination in view of the following amendments and remarks.

Please amend the above-identified application as follows:

**Amendments To The Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.

**Attachments:** Document A (*The Journal of Pharmacology and Experimental Therapeutics*, Vol. 262, No. 3, (1992) (pp. 1214-1219); Document B (*The Journal of Pharmacology and Experimental Therapeutics*, Vol. 271, No. 3, (1994) (pp. 1672-1677); and Document C: *Toxicology and Applied Pharmacology* 194 (2004) (pp. 180-188) are attached after page 9 of this paper.